New myelodysplastic syndrome drug 'Reblozyl' lands Big 5 DC
By Eo, Yun-Ho | translator Hong, Ji Yeon
24.09.30 05:39:00
°¡³ª´Ù¶ó
0
Has passed drug committees (DC) of Seoul National University Hospital, St. Mary's Hospital, and Asan Medical Center
Still non-reimbursable after failing the DREC review in August last year
¡ãProduct photo of Reblozyl.
The treatment for myelodysplastic syndrome (MDS), 'Reblozyl,' is available for prescription at tertiary general hospitals. Sources said that Bristol Myers Squibb (BMS) Pharmaceutical Korea's Reblozyl (luspatercept) has passed all drug committees (DC) of the 'Big 5' medical centers, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Seoul Asan Medical Center, and Sinchon Severance Hospital.
However, Reblozyl is still non-reimbursable. The drug was not approved for reimbursement appropriateness at the Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA), held August last year. It has not b
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)